Related Experiment Videos
Metabonomics: a platform for studying drug toxicity and gene function.
Jeremy K Nicholson1, John Connelly, John C Lindon
1Biological Chemistry Section, Biomedical Sciences Division, Faculty of Medicine, Imperial College of Science, Technology and Medicine, South Kensington, London SW7 2AZ, UK. j.nicholson@ic.ac.uk
Nature Reviews. Drug Discovery
|July 18, 2002
Summary
Minimizing drug candidate loss in pharmaceutical development is crucial for saving resources and ensuring profitability. Metabonomics, a systems approach, offers early insights into drug toxicity and efficacy, improving decision-making in drug discovery.
Area of Science:
- Pharmacology and Toxicology
- Systems Biology
- Drug Discovery and Development
Background:
- High attrition rates in drug development lead to significant financial losses.
- Early identification of non-viable drug candidates is essential for efficient resource allocation.
- Novel technologies are needed to improve the accuracy of early-stage drug selection.
Purpose of the Study:
- To highlight the importance of minimizing attrition in pharmaceutical discovery.
- To introduce metabonomics as a novel technology for early-stage drug development.
- To demonstrate the potential of metabonomics in assessing drug toxicity and efficacy.
Main Methods:
- Utilizing metabonomics as a systems approach to analyze in vivo metabolic profiles.
- Applying metabonomics at various stages of the drug discovery and development process.
- Integrating metabolic profiling data to inform decision-making.
Main Results:
- Metabonomics provides valuable information on drug toxicity, disease processes, and gene function.
- Early application of metabonomics can increase the probability of selecting viable drug candidates.
- This systems approach aids in saving resources and promoting profitability.
Conclusions:
- Metabonomics is a promising technology for improving the efficiency and success rate of drug development.
- Early assessment of metabolic profiles can mitigate financial risks associated with late-stage attrition.
- Implementing metabonomics supports the development of safer and more effective therapeutics.